OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

Bernadette Dian Novita, MD.,PhD

Status: Completed

Conditions: Clinical Manifestation of COVID-19; Duration of Hospitalization

Treatments: Drug: Remdesivir

Study type: Observational

Funder types: Other

Identifiers

NCT05222113

148/WM12/KEPK/MHSW

Details and patient eligibility

About

In order to compare the effectiveness between Remdesivir and Favipiravir, an observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021

Full description

Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). Antiviral therapies are considered to be one of the COVID-19 treatments. Remdesivir and favipiravir are the antivirals recommended by Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism to inhibit virus replication, specifically by inhibiting RNA-dependent RNA polymerase (RdRp) of the virus. Several studies reported that patients who received these antivirals had a lower duration of hospitalization. However, the effectiveness comparison of remdesivir and favipiravir remains unknown.

An observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021 are collected by consecutive sampling technique, and this research was carried out at Gotong Royong Hospital Surabaya.

Enrollment: 87 patients

Sex: All

Ages: 18 to 97 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (eighteen years old or above) with moderate to severe COVID-19 (categorized based on KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK. 01. 07/MENKES/413/2020);
• Admitted to Gotong Royong Hospital Surabaya from January 2021 to August 2021;
• Received remdesivir OR favipiravir with minimal five days of treatment
• Not in pregnancy and lactating condition

Exclusion criteria

• female patient with pregnancy and lactation
• patient whom was passed away or forced home during two-weeks observation period